Author | Xiao Yu Periodically, major pharmaceutical media and authoritative journals summarize the development of Antibody-Drug Conjugates (ADCs). Recently, a review on ADCs published by the internationally renowned journal ACS was particularly eye-catching. As a member of CAS (a division of the American Chemical Society), Janet M. Sasso’s team innovatively utilized patents and articles related … Read more
Introduction Although rare, intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignant tumor of the liver, with approximately 8,000 cases diagnosed annually in the United States, accounting for only 3% of gastrointestinal malignancies diagnosed worldwide each year. The incidence of ICC has increased over the past few decades, with some studies indicating a 14% … Read more
Introduction All cells, both eukaryotic and prokaryotic, secrete extracellular vesicles, and exosomes are a type of extracellular vesicle, ranging in size from 40 – 160 nm (average 100 nm). Depending on their cellular origin, they contain various components, including DNA, RNA, lipids, metabolites, and cytoplasmic and cell surface proteins. Their physiological purpose is not yet … Read more
1. Ladder Diagram (LAD) Ladder Diagram language is derived from the commonly used relay and contactor logical control, simplifying the evolution of symbols. It is intuitive, practical, and easily accepted by electrical technicians, making it the most widely used programming language for PLCs today. In a PLC program diagram, the left and right buses are … Read more
Click the "Little White Learns Vision" above, choose to add "Star" or "Top" Heavyweight content delivered to you at the first time From the perspective of underlying hardware, I analyzed how the CPU recognizes and reads code. The content is so wonderful that after reading it, I felt that many things I learned suddenly connected … Read more
Introduction In addition to the need for ADCs to target antigens that are overexpressed in tumors, another important factor is the efficiency of endocytosis, which is necessary for the release of the drug’s active payload. In fact, the efficacy of ADCs depends on the efficiency of targeted-mediated internalization to deliver effective payloads within tumor cells. … Read more
Introduction Antibody-drug conjugates (ADCs) are composed of monoclonal antibodies targeting specific antigens linked to small molecule cytotoxic drugs via linkers. They combine the strong killing effect of traditional small molecule chemotherapy with the tumor-targeting ability of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the … Read more
Immunotherapy brings hope for the complete cure of cancer by activating the human immune system to kill tumors. Currently, most approved immunotherapies show significant effects in hematological tumors, but have low response rates and poor efficacy in solid tumors. The main reason is the complex and highly heterogeneous tumor immune microenvironment in solid tumors, where … Read more
In 2024, the National Cancer Center of China released the latest data based on tumor registration and follow-up monitoring on the JNCC,2022 cancer burden in China. The results published this time are jointly calculated by the National Cancer Center and the International Agency for Research on Cancer (IARC), consistent with the Chinese data released by … Read more
1 Introduction Antibody-drug conjugates (ADCs) are a new type of highly effective biopharmaceuticals that link antibodies with biologically active small molecule cytotoxic payloads through linkers. ADCs are designed to improve the therapeutic index (TI) of chemotherapeutic agents by selectively delivering cytotoxic drugs to tumor cells while reducing exposure in normal cells. Despite using a large … Read more